Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-355: Pembrolizumab plus chemotherapy vs placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
2016-001432-35Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Part 1 safety endpoints and Part 2 efficacy endpoints. Started May 2016; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-001432-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001432-35.